The ways by which the potential to differentiate leukemic cells from healthy cells provides an opportunity to develop a therapy for CML treatment. Introduction: In the case of CML (chronic myelogenous leukemia), leukemic cells can be distinguished from healthy body cells. This difference occurs due to the presence of functional BCR-ABL hybrid protein.

Question

Want to see more full solutions like this?

Answer 1

Question

Chapter 24, Problem 1NST

Summary Introduction

To determine: The ways by which the potential to differentiate leukemic cells from healthy cells provides an opportunity to develop a therapy for CML treatment.

Introduction: In the case of CML (chronic myelogenous leukemia), leukemic cells can be distinguished from healthy body cells. This difference occurs due to the presence of functional BCR-ABL hybrid protein.

Expert Solution & Answer

Explanation of Solution

One of the approaches that can be utilized to fight CML includes the use of tyrosine kinase inhibitor. This inhibitor binds to the ATP binding site of ABL kinase by inhibiting BCR-ABL phosphorylation and preventing the activation signaling pathways.

Moreover, real-time Q-RT-PCR (quantitative reverse transcription-polymerase chain reaction) allows an individual to monitor drug responses of cell populations in the patient. This approach is used to develop less toxic and effective treatments.

The potential to differentiate leukemic cells from normal cells allows an individual not to target therapy to specific cell populations but also to quantify responses to therapy. The leukemic cells produce an unusual hybrid protein known as BCR-ABL. Therefore, it may be possible to develop a therapy such as immunotherapy, based on the uniqueness of BCR-ABL protein.

Conclusion

Thus, the uniqueness of BCR-ABL protein may be used to develop immunotherapy for CML treatment.

Want to see more full solutions like this?

Subscribe now to access step-by-step solutions to millions of textbook problems written by subject matter experts!

Students have asked these similar questions

Ch.23 How is Salmonella able to cross from the intestines into the blood? A. it is so small that it can squeeze between intestinal cells B. it secretes a toxin that induces its uptake into intestinal epithelial cells C. it secretes enzymes that create perforations in the intestine D. it can get into the blood only if the bacteria are deposited directly there, that is, through a puncture — Which virus is associated with liver cancer? A. hepatitis A B. hepatitis B C. hepatitis C D. both hepatitis B and C — explain your answer thoroughly

Ch.21 What causes patients infected with the yellow fever virus to turn yellow (jaundice)? A. low blood pressure and anemia B. excess leukocytes C. alteration of skin pigments D. liver damage in final stage of disease — What is the advantage for malarial parasites to grow and replicate in red blood cells? A. able to spread quickly B. able to avoid immune detection C. low oxygen environment for growth D. cooler area of the body for growth — Which microbe does not live part of its lifecycle outside humans? A. Toxoplasma gondii B. Cytomegalovirus C. Francisella tularensis D. Plasmodium falciparum — explain your answer thoroughly

Ch.22 Streptococcus pneumoniae has a capsule to protect it from killing by alveolar macrophages, which kill bacteria by… A. cytokines B. antibodies C. complement D. phagocytosis — What fact about the influenza virus allows the dramatic antigenic shift that generates novel strains? A. very large size B. enveloped C. segmented genome D. over 100 genes — explain your answer thoroughly

Answer 2

Question

Chapter 24, Problem 1NST

Summary Introduction

To determine: The ways by which the potential to differentiate leukemic cells from healthy cells provides an opportunity to develop a therapy for CML treatment.

Introduction: In the case of CML (chronic myelogenous leukemia), leukemic cells can be distinguished from healthy body cells. This difference occurs due to the presence of functional BCR-ABL hybrid protein.

Expert Solution & Answer

Explanation of Solution

One of the approaches that can be utilized to fight CML includes the use of tyrosine kinase inhibitor. This inhibitor binds to the ATP binding site of ABL kinase by inhibiting BCR-ABL phosphorylation and preventing the activation signaling pathways.

Moreover, real-time Q-RT-PCR (quantitative reverse transcription-polymerase chain reaction) allows an individual to monitor drug responses of cell populations in the patient. This approach is used to develop less toxic and effective treatments.

The potential to differentiate leukemic cells from normal cells allows an individual not to target therapy to specific cell populations but also to quantify responses to therapy. The leukemic cells produce an unusual hybrid protein known as BCR-ABL. Therefore, it may be possible to develop a therapy such as immunotherapy, based on the uniqueness of BCR-ABL protein.

Conclusion

Thus, the uniqueness of BCR-ABL protein may be used to develop immunotherapy for CML treatment.

Want to see more full solutions like this?

Subscribe now to access step-by-step solutions to millions of textbook problems written by subject matter experts!

Answer 3

Question

Chapter 24, Problem 1NST

Summary Introduction

To determine: The ways by which the potential to differentiate leukemic cells from healthy cells provides an opportunity to develop a therapy for CML treatment.

Introduction: In the case of CML (chronic myelogenous leukemia), leukemic cells can be distinguished from healthy body cells. This difference occurs due to the presence of functional BCR-ABL hybrid protein.

Expert Solution & Answer

Explanation of Solution

One of the approaches that can be utilized to fight CML includes the use of tyrosine kinase inhibitor. This inhibitor binds to the ATP binding site of ABL kinase by inhibiting BCR-ABL phosphorylation and preventing the activation signaling pathways.

Moreover, real-time Q-RT-PCR (quantitative reverse transcription-polymerase chain reaction) allows an individual to monitor drug responses of cell populations in the patient. This approach is used to develop less toxic and effective treatments.

The potential to differentiate leukemic cells from normal cells allows an individual not to target therapy to specific cell populations but also to quantify responses to therapy. The leukemic cells produce an unusual hybrid protein known as BCR-ABL. Therefore, it may be possible to develop a therapy such as immunotherapy, based on the uniqueness of BCR-ABL protein.

Conclusion

Thus, the uniqueness of BCR-ABL protein may be used to develop immunotherapy for CML treatment.

Want to see more full solutions like this?

Subscribe now to access step-by-step solutions to millions of textbook problems written by subject matter experts!

Answer 4

Question

Chapter 24, Problem 1NST

Summary Introduction

To determine: The ways by which the potential to differentiate leukemic cells from healthy cells provides an opportunity to develop a therapy for CML treatment.

Introduction: In the case of CML (chronic myelogenous leukemia), leukemic cells can be distinguished from healthy body cells. This difference occurs due to the presence of functional BCR-ABL hybrid protein.

Expert Solution & Answer

Explanation of Solution

One of the approaches that can be utilized to fight CML includes the use of tyrosine kinase inhibitor. This inhibitor binds to the ATP binding site of ABL kinase by inhibiting BCR-ABL phosphorylation and preventing the activation signaling pathways.

Moreover, real-time Q-RT-PCR (quantitative reverse transcription-polymerase chain reaction) allows an individual to monitor drug responses of cell populations in the patient. This approach is used to develop less toxic and effective treatments.

The potential to differentiate leukemic cells from normal cells allows an individual not to target therapy to specific cell populations but also to quantify responses to therapy. The leukemic cells produce an unusual hybrid protein known as BCR-ABL. Therefore, it may be possible to develop a therapy such as immunotherapy, based on the uniqueness of BCR-ABL protein.

Conclusion

Thus, the uniqueness of BCR-ABL protein may be used to develop immunotherapy for CML treatment.

Want to see more full solutions like this?

Subscribe now to access step-by-step solutions to millions of textbook problems written by subject matter experts!

Answer 5

Chapter 24, Problem 1NST

Summary Introduction

To determine: The ways by which the potential to differentiate leukemic cells from healthy cells provides an opportunity to develop a therapy for CML treatment.

Introduction: In the case of CML (chronic myelogenous leukemia), leukemic cells can be distinguished from healthy body cells. This difference occurs due to the presence of functional BCR-ABL hybrid protein.

Expert Solution & Answer

Explanation of Solution

One of the approaches that can be utilized to fight CML includes the use of tyrosine kinase inhibitor. This inhibitor binds to the ATP binding site of ABL kinase by inhibiting BCR-ABL phosphorylation and preventing the activation signaling pathways.

Moreover, real-time Q-RT-PCR (quantitative reverse transcription-polymerase chain reaction) allows an individual to monitor drug responses of cell populations in the patient. This approach is used to develop less toxic and effective treatments.

The potential to differentiate leukemic cells from normal cells allows an individual not to target therapy to specific cell populations but also to quantify responses to therapy. The leukemic cells produce an unusual hybrid protein known as BCR-ABL. Therefore, it may be possible to develop a therapy such as immunotherapy, based on the uniqueness of BCR-ABL protein.

Conclusion

Thus, the uniqueness of BCR-ABL protein may be used to develop immunotherapy for CML treatment.

Answer 6

Chapter 24, Problem 1NST

Summary Introduction

To determine: The ways by which the potential to differentiate leukemic cells from healthy cells provides an opportunity to develop a therapy for CML treatment.

Introduction: In the case of CML (chronic myelogenous leukemia), leukemic cells can be distinguished from healthy body cells. This difference occurs due to the presence of functional BCR-ABL hybrid protein.

Expert Solution & Answer

Explanation of Solution

One of the approaches that can be utilized to fight CML includes the use of tyrosine kinase inhibitor. This inhibitor binds to the ATP binding site of ABL kinase by inhibiting BCR-ABL phosphorylation and preventing the activation signaling pathways.

Moreover, real-time Q-RT-PCR (quantitative reverse transcription-polymerase chain reaction) allows an individual to monitor drug responses of cell populations in the patient. This approach is used to develop less toxic and effective treatments.

The potential to differentiate leukemic cells from normal cells allows an individual not to target therapy to specific cell populations but also to quantify responses to therapy. The leukemic cells produce an unusual hybrid protein known as BCR-ABL. Therefore, it may be possible to develop a therapy such as immunotherapy, based on the uniqueness of BCR-ABL protein.

Conclusion

Thus, the uniqueness of BCR-ABL protein may be used to develop immunotherapy for CML treatment.

Answer 7

Chapter 24, Problem 1NST

Summary Introduction

To determine: The ways by which the potential to differentiate leukemic cells from healthy cells provides an opportunity to develop a therapy for CML treatment.

Introduction: In the case of CML (chronic myelogenous leukemia), leukemic cells can be distinguished from healthy body cells. This difference occurs due to the presence of functional BCR-ABL hybrid protein.

Answer 8

Expert Solution & Answer

Explanation of Solution

One of the approaches that can be utilized to fight CML includes the use of tyrosine kinase inhibitor. This inhibitor binds to the ATP binding site of ABL kinase by inhibiting BCR-ABL phosphorylation and preventing the activation signaling pathways.

Moreover, real-time Q-RT-PCR (quantitative reverse transcription-polymerase chain reaction) allows an individual to monitor drug responses of cell populations in the patient. This approach is used to develop less toxic and effective treatments.

The potential to differentiate leukemic cells from normal cells allows an individual not to target therapy to specific cell populations but also to quantify responses to therapy. The leukemic cells produce an unusual hybrid protein known as BCR-ABL. Therefore, it may be possible to develop a therapy such as immunotherapy, based on the uniqueness of BCR-ABL protein.

Answer 9

Expert Solution & Answer

Answer 10

Expert Solution & Answer

Answer 11

Conclusion

Thus, the uniqueness of BCR-ABL protein may be used to develop immunotherapy for CML treatment.

Answer 12

Ch. 24 - Prob. 1NST Ch. 24 - People with a genetic condition known as...Ch. 24 - Prob. 3NST Ch. 24 - Cancer can arise spontaneously, but it can also be...Ch. 24 - Prob. 1CS Ch. 24 - Prob. 2CS Ch. 24 - If you agree to participate and then learn that...Ch. 24 - HOW DO WE KNOW? In this chapter, we focused on...Ch. 24 - Prob. 2PDQ Ch. 24 - Where are the major regulatory points in the cell...

Concept explainers

Explanation of Solution

Want to see more full solutions like this?

Chapter 24 Solutions